Press Releases on June 5, 2023 - EIN Presswire - Press Release Distribution Service

Published on June 5, 2023 - 11:00 GMT

Oregon Pawnshop Donates to Local Charity Supporting Parents with Cancer

Capital Pawn and Couture announced their recent support of Oregon nonprofit, Michelle's Love. SALEM, OR, UNITED STATES, June 5, 2023 /⁨EINPresswire.com⁩/ -- Capital Pawn and Couture, a local pawnshop with five locations throughout the …

Distribution channels: Business & Economy, Retail ...

Published on June 5, 2023 - 11:00 GMT

Snax-Sational Brands Continues Support of Ryan Seacrest Foundation As They Unveil Latest Broadcast Studio In Memphis, TN

The Snack Industry Innovator Joined Ryan Seacrest And The RSF Foundation Team As They Unveiled Latest Broadcast Studio At Le Bonheur Children’s Hospital MEMPHIS, TN, UNITED STATES, June 5, 2023 /⁨EINPresswire.com⁩/ -- For Immediate Release: Le …

Distribution channels: Consumer Goods, Culture, Society & Lifestyle ...

Published on June 5, 2023 - 10:59 GMT

Air Ambulance Services Market : Release Latest Trends & Industry Vision 2030 | Coherent Market Insights

SEATTLE, WASHINGTON, INDIA, June 5, 2023 /⁨EINPresswire.com⁩/ -- Air Ambulance Services Market Report Study The exclusive research report on ‘Air Ambulance Services Market‘ now available with Coherent Market Insights, offers a detailed analysis of the …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment ...

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities DT-9045 is a unique drug candidate due to its competitive differentiating pharmacological features Start of Phase 1 …

Distribution channels: Media, Advertising & PR, Technology ...

Published on June 5, 2023 - 11:00 GMT

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets Lotus Pharmaceuticals will acquire worldwide …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief ...

Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise Adding further oncology experience to Immodulon’s leadership team as the company prepares to advance IMM-101 into a pivotal …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01

ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01 ANT-01 in development as an adjunctive treatment for Major Depressive Disorder (MDD), with minimal side effects Phase IIIB trial to begin …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on June 5, 2023 - 11:00 GMT

Bofu Agence Marketing Obtains The CONCILIVI Seal

SAINT-JÉRÔME, Quebec, June 05, 2023 (GLOBE NEWSWIRE) -- We are proud to announce that Bofu Agence Marketing recently obtained the CONCILIVI seal, which recognizes companies advocating better work-family balance for its employees. This recognition …

Distribution channels:

Published on June 5, 2023 - 11:00 GMT

Bofu Agence Marketing est détenteur du sceau CONCILIVI

SAINT-JÉRÔME, Québec, 05 juin 2023 (GLOBE NEWSWIRE) -- Nous sommes fiers d’annoncer que Bofu Agence Marketing a récemment obtenu le sceau CONCILIVI qui reconnaît les entreprises prônant une meilleure conciliation travail-famille pour ses employés. Cette …

Distribution channels:

Published on June 5, 2023 - 11:00 GMT

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic ...

– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – – Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. ( …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on June 5, 2023 - 11:00 GMT

Prenetics Announces First Quarter 2023 Financial Results

HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Vision Energy Concludes Pre-FEED Study

JERSEY CITY, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Vision Energy Corporation (OTC:VENG) (“Vision Energy” or the “Company”) is pleased to announce it has concluded the pre-FEED study for all Phase 1 Green Ammonia infrastructure at its Green Energy Hub …

Distribution channels: Energy Industry ...

Published on June 5, 2023 - 11:00 GMT

Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Harsco Corporation announces name change to Enviri Corporation

New brand identity better reflects Company’s commitment to developing and refining sustainable solutions to help solve complex environmental challenges PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Harsco Corporation (NYSE: HSC) will change its name to …

Distribution channels: Technology ...

Published on June 5, 2023 - 11:00 GMT

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

JIANGSU, China, June 05, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide therapeutics, today announced the dosing of its first patient in the …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen ...

Tianeptine’s Mechanism of Restoring Neuroplasticity and Neurogenesis by Dual PPAR-β/δ and PPAR-γ Agonism Supports Development as a First-in-Class Oral Therapy for Psychiatric and Neurodegenerative Diseases Racemic Tianeptine, or TNX-601 ER, is …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive ...

-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care over all twice-nightly oxybates DUBLIN, Ireland, June 05, …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on June 5, 2023 - 11:00 GMT

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese ...

-- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0% Median Reduction in non-HDL-C from Baseline (p < 0.0001) …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 5, 2023 - 11:00 GMT

Hammerhead Energy Inc. announces results of its substantial issuer bid

CALGARY, Alberta, June 05, 2023 (GLOBE NEWSWIRE) -- Hammerhead Energy Inc. ("Hammerhead" or "HEI") (TSX: HHRS, HHRS.WT ; NASDAQ: HHRS, HHRSW) announces the results of its substantial issuer bid (the "Offer"), pursuant to which …

Distribution channels: Energy Industry ...

Published on June 5, 2023 - 11:00 GMT

Diversified Royalty Corp. Announces Completion of BMO Acquisition of Air MILES Reward Program Business and June 2023 Cash Dividend ...

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce that on June 1, 2023 the Bank of Montreal (“BMO”) issued a news release (the “BMO News …

Distribution channels: Banking, Finance & Investment Industry ...